Showing 20 of 26 results
GIC进一步增持歌礼制药-B（1672.HK）超1千万股 持股比例升至7.00% 彰显长期发展信心
HealthcareMay 12, 2026 19:12 HKT/SGT
HONG KONG May, 12, 2026 (ACN Newswire) - 歌礼制药-B（1672.HK）获新加坡政府投资公司（GIC）进一步增持。根据最新权益披露显示，GIC于5月7日以每股均价16.612港元增持歌礼制药12.2万股普通股，价值约202.67万港元。增持后，GIC持股数量增加超1000万股，增至7,480.8万股，持股比例提升至7.00%。此前，GIC已于今年2月通过Pl
GIC進一步增持歌禮製藥-B（1672.HK）超1千萬股 持股比例升至7.00% 彰顯長期發展信心
HealthcareMay 12, 2026 19:12 HKT/SGT
HONG KONG May, 12, 2026 (ACN Newswire) - 歌禮製藥-B（1672.HK）獲新加坡政府投資公司（GIC）進一步增持。根據最新權益披露顯示，GIC於5月7日以每股均價16.612港元增持歌禮製藥12.2萬股普通股，價值約202.67萬港元。增持後，GIC持股數量增加超1000萬股，增至7,480.8萬股，持股比例提升至7.00%。此前，GIC已於今年2月通過Pl
梁瑞安博士受邀出席英国2026 LifeArc转化科学峰会
HealthcareSinoMab BioScience Limited
•
May 13, 2026 09:17 HKT/SGT
HONG KONG May, 13, 2026 (ACN Newswire) - 中国抗体制药有限公司（"中国抗体"或"公司"，连同旗下附属公司统称"集团"，股份代号：03681.HK）欣然宣布，公司执行董事、主席兼首席执行官梁瑞安博士作为特邀嘉宾，出席了近日在英国伦敦举办的2026 LifeArc转化科学峰会（LifeArc Trans
Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK
HealthcareSinoMab BioScience Limited
•
May 13, 2026 09:06 HKT/SGT
HONG KONG May, 13, 2026 (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group'; stock code: 03681.HK) is ple
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
HealthcareWellgistics Health, Inc.
•
May 13, 2026 21:05 HKT/SGT
TAMPA, FLA. May, 13, 2026 (ACN Newswire) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution
Wellgistics Health宣布与Kare PharmTech开展MSO试点合作，瞄准美国价值140亿美元的慢性病管理（CCM）和远程患者监测（RPM）服务市场
HealthcareWellgistics Health, Inc.
•
May 13, 2026 21:05 HKT/SGT
TAMPA, FLA. May, 13, 2026 (ACN Newswire) - 领先的医疗科技与药品分销公司 Wellgistics Health, Inc.（纳斯达克代码：WGRX）（以下简称“Wellgistics”或“公司”）今日宣布，将与 Kare PharmTech 和 Kare Clinicals 开展试点合作，整合其管理服务组织（MSO）基础设施，以支持参与该计划的医疗机构开展
Wellgistics Health 宣布與 Kare PharmTech 展開醫療服務組織 (MSO) 試點合作，目標鎖定規模達 140 億美元的美國疾病管理 (CCM) 與遠程患者監測 (RPM) 服務市場
HealthcareWellgistics Health, Inc.
•
May 13, 2026 21:05 HKT/SGT
TAMPA, FLA. May, 13, 2026 (ACN Newswire) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.（納斯達克代碼：WGRX）（以下簡稱「Wellgistics」或「本公司」）今日宣布，將與 Kare PharmTech 及 Kare Clinicals 展開試點合作，整合其醫療服務組織（MSO）基礎設施，以支援參與計畫的醫療機構所提
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully
BusinessHKTDC
•
May 13, 2026 19:55 HKT/SGT
HONG KONG May, 13, 2026 (ACN Newswire) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Devel
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
HealthcareWellgistics Health, Inc.
•
May 15, 2026 07:00 HKT/SGT
TAMPA, FLA. May, 15, 2026 (ACN Newswire) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution
Wellgistics Health 计划收购 WellCare Today 及其专有的三星 Galaxy Watch 护理监测项目，以此加速其新近宣布的远程患者监测（RPM）、远程治疗管理（RTM）和慢性病管理（CCM）试点项目的数字健康业务拓展
HealthcareWellgistics Health, Inc.
•
May 15, 2026 07:00 HKT/SGT
TAMPA, FLA. May, 15, 2026 (ACN Newswire) - 领先的医疗健康技术与药品分销公司 Wellgistics Health, Inc.（纳斯达克代码：WGRX）（以下简称“Wellgistics”或“公司”）今日宣布，已签署一份收购 WellCare Today 的非约束性意向书（“LOI”）。拟议的交易结构包括300万美元的现金支付，剩余部分将通过以优先股形式发
Wellgistics Health 透過計劃收購 WellCare Today 及其專屬的 Samsung Galaxy Watch 照護監測計畫，加速其新近宣布的遠端患者監測（RPM）、遠端治療管理（RTM）及慢性病管理（CCM）試點計畫的數位健康擴展
HealthcareWellgistics Health, Inc.
•
May 15, 2026 07:00 HKT/SGT
TAMPA, FLA. May, 15, 2026 (ACN Newswire) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.（納斯達克代碼：WGRX）（「Wellgistics」或「本公司」）今日宣布，已簽署一份非約束性意向書（「LOI」），擬收購 WellCare Today。擬議的交易結構包括300萬美元的結構化現金付款，餘額將透過以優先股形式發行的績效
云顶新耀主要股东傅唯再度增持 年内第二次加仓彰显长期信心
HealthcareEverest Medicines Limited
•
May 15, 2026 13:00 HKT/SGT
HONG KONG May, 15, 2026 (ACN Newswire) - 云顶新耀（HKEX 1952.HK）发布公告，基于对公司未来前景及长远发展的坚定信心，公司非执行董事、董事会荣誉主席兼主要股东傅唯先生于2026年5月14日通过公开市场购入公司普通股66万股，并表示不排除在适当时候进一步增持。本次交易总金额约为2070万港元，平均价格约为每股31.25港元。这
雲頂新耀主要股東傅唯再度增持 年內第二次加倉彰顯長期信心
HealthcareEverest Medicines Limited
•
May 15, 2026 13:00 HKT/SGT
HONG KONG May, 15, 2026 (ACN Newswire) - 雲頂新耀（HKEX 1952.HK）發佈公告，基於對公司未來前景及長遠發展的堅定信心，公司非執行董事、董事會榮譽主席兼主要股東傅唯先生於2026年5月14日通過公開市場購入公司普通股66萬股，並表示不排除在適當時候進一步增持。本次交易總金額約為2070萬港元，平均價格約為每股31.25港元。這
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
FinanceEverest Medicines Limited
•
May 15, 2026 13:00 HKT/SGT
HONG KONG May, 15, 2026 (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) announced that on 14 May 2026, based on strong confidence in the company's future prospects and long-term development, M
Fujitsu and IBM Japan formalize collaboration in healthcare sector
TechnologyFujitsu Ltd
•
May 15, 2026 15:42 HKT/SGT
Kawasaki and Tokyo, Japan May, 15, 2026 (JCN Newswire) - Fujitsu Limited and IBM Japan, Ltd. today announced the formalization of a collaboration within the healthcare domain, building on consideratio
エーザイ、「SX 銘柄 2026」に初選定
HealthcareEisai
•
May 18, 2026 14:50 HKT/SGT
TOKYO May, 18, 2026 (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、経済産業省と東京証券取引所が共同で選定・表彰する「SX 銘柄 2026」に初めて選定されましたので、お知らせします。SX（サステナビリティ・トランスフォーメーション）とは、社会のサステナビリティ課題に由来する中長期的なリスクや
SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
HealthcareFujitsu Ltd
•
May 19, 2026 12:37 HKT/SGT
Tokyo and Kawasaki, Japan May, 19, 2026 (JCN Newswire) - Sumitomo Mitsui Financial Group, Inc. (SMBC Group), Fujitsu Limited (Fujitsu), and SoftBank Corp. (SoftBank) today announced they entered into
Graphene quantum dots show promise in targeting Parkinson's-related protein clumping
TechnologyScience and Technology of Advanced Materials
•
May 20, 2026 17:00 HKT/SGT
TSUKUBA, Japan May, 20, 2026 (ACN Newswire) - The buildup of a protein called a-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that include
エーザイ、米国臨床腫瘍学会年次総会（ASCO）において、「レンビマ(R)」（レンバチニブ）の承認済み適応症に関する臨床エビデンスを補強する最新データを発表
HealthcareEisai
•
May 21, 2026 16:45 HKT/SGT
TOKYO May, 21, 2026 (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2026 年 5 月 29 日から6 月 2 日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2026 ASCO Annual Me
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
HealthcareEisai
•
May 21, 2026 23:23 HKT/SGT
TOKYO May, 21, 2026 (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and